CDK46estäjiä

CDK46estäjiä refers to a class of drugs that inhibit cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases play a crucial role in cell cycle progression, specifically in the transition from the G1 phase to the S phase. By blocking CDK4 and CDK6, these inhibitors prevent the phosphorylation of the retinoblastoma protein (Rb), which in turn halts cell proliferation. This mechanism makes CDK46estäjiä valuable in treating certain types of cancer, particularly hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

The development of CDK46estäjiä has marked a significant advancement in breast cancer therapy. These drugs are typically used in combination with endocrine therapy, such as aromatase inhibitors or fulvestrant, to achieve a greater anti-tumor effect than endocrine therapy alone. The rationale behind this combination is that endocrine therapy targets the estrogen receptor pathway, while CDK46estäjiä directly addresses the uncontrolled cell division that can occur even in the presence of endocrine blockade. Clinical trials have demonstrated that adding a CDK46estäjä to endocrine therapy significantly improves progression-free survival and, in some cases, overall survival for patients with HR+/HER2- metastatic breast cancer.

Common side effects associated with CDK46estäjiä include neutropenia (low white blood cell count), fatigue, nausea, and diarrhea. Regular monitoring of blood counts is essential during treatment to manage potential hematological toxicities. While generally well-tolerated, adherence to treatment and management of side effects are important for optimizing patient outcomes. The introduction of CDK46estäjiä has become a standard of care in the first-line treatment of many patients with this specific subtype of breast cancer.

---